Protocol Ledger

NCT04025372 · Phase II · ACTIVE NOT RECRUITING

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Interventional Phase II clinical trial protocol NCT04025372 sponsored by Brigham and Women's Hospital in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-06-01 Enrollment: 234 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04025372
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)234 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04025372
Protocol FieldVerified Registry Value
NCT IdentifierNCT04025372
Consolidated Lead SponsorBrigham and Women's Hospital
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment234 participants (ACTUAL)
Registered Start Date2020-06-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04025372
Hospital Research SiteLocationSite Profile
Brigham and Women's HospitalBoston, MAOpen Hospital Dossier ->
Dana-Farber Cancer InstituteBoston, MAOpen Hospital Dossier ->
Washington University and Siteman Cancer CenterSaint Louis, MOOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Mass General Brigham across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI